Beacon Biosignals
Boston, United States · Information Technology, Software
Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological, psychiatric or sleep disorders. Through novel machine learning algorithms, large datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain.
Key facts
- Headquarters
- Boston, United States
- Employees
- 103
- Industries
- Information Technology, Software
- Status
- Private
- Website
- beacon.bio
- Company page
Recent activity at Beacon Biosignals
- : Beacon Biosignals raises $11M in a Series B extension, bringing total funding to over $97M. New investors include JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next.
- : Beacon Biosignals raises $86M in Series B funding led by Innoviva and Google Ventures to scale its technology for neurobiomarker discovery.
- : Beacon Biosignals Launches FDA-Authorized Dreem 3S Sleep Wearable with Continuous Improvement Capabilities.
- : Beacon Biosignals and Skye Bioscience, Inc. Collaborate to Enhance CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
- : Beacon Biosignals and Skye Bioscience, Inc. Collaborate to Enhance CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
- : Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer
- : Beacon Biosignals Acquires Dreem, Launches At-Home Sleep Monitoring Services For Clinical Trials
- : Beacon Biosignals Raises $27 Million Series A Led By General Catalyst To Scale Its Eeg Neurobiomarker Discovery Platform
- : Beacon Biosignals, Inc.
- : Checkpoint AI, Inc.
Beacon Biosignals funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Series B | $103.3M |
| Nov 2025 | Series B | $86.0M |
| Nov 2021 | Series A | $27.0M |
| Oct 2021 | Venture | $29.9M |
| Feb 2019 | Pre-Seed | $50K |
Leadership
- Jacob Donoghue, Co-Founder and CEO
- Naveen Rao, Director
- Jacob Donoghue, Executive Officer, Director, Promoter
- Emily Mitchell, Vice President, Clinical Study Operations
- Amaelle Bidet, Neuroscience Ph D Candidate
- Karolina Blaszczuk, Manager, Quality Assurance
- Alexander Chan, VP, Analytics and Machine Learning
- Emily Mitchell, Vice President, Clinical Study Operations
- Jacob Donoghue, Co Founder and CEO
- Srihari Sritharan, Business Development Manager
- Megan Means, Head of People & Talent
- Antoine Guillot, Senior Manager, Algorithms
Verified email and direct lines for Beacon Biosignals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Beacon Biosignals files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Beacon Biosignals in the news
- Beacon Biosignals is mapping the brain during sleep - MIT News (May 01, 2026)
- Beacon Biosignals Receives FDA Clearance for AI-Assisted Sleep Monitoring Device Dreem 3S - PR Newswire (Sep 14, 2023)
- Beacon Biosignals inks licensing deal with Takeda worth up to $109M - MassDevice (Nov 19, 2025)
- Beacon Biosignals Raises $11M; Brings Series B Financing to Over $97M - FinSMEs (Apr 06, 2026)
- Beacon Biosignals Appoints David Matthews, PhD, as Chief Business Officer - citybiz (Feb 01, 2024)
- FDA Authorizes Beacon's Dreem 3S as First Sleep Wearable with Predetermined Change Control Plan, Paving the Way for Continuous Algorithm Enhancements in Sleep Monitoring - The Manila Times (Dec 03, 2024)
- Beacon Biosignals raises $27 Million Series A led by General Catalyst to scale its EEG neurobiomarker discovery platform - PR Newswire (Nov 08, 2021)
- Beacon Biosignals Acquires Dreem, Launches At-home Sleep Monitoring Services for Clinical Trials - PR Newswire (Jul 11, 2023)
Companies similar to Beacon Biosignals
- Proscia · Information Technology, Software
- FreightVerify · Information Technology, Software
- Asolvi · Information Technology, Software
- Voxel · Information Technology, Software
- Arkestro · Information Technology, Software
About Beacon Biosignals: questions and answers
What does Beacon Biosignals do?
Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological, psychiatric or sleep disorders. Through novel machine learning algorithms, large datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain.
Where is Beacon Biosignals headquartered?
Beacon Biosignals is headquartered in Boston, United States.
How many employees does Beacon Biosignals have?
Beacon Biosignals has about 103 employees.
Has Beacon Biosignals raised funding?
Yes. Fundz has recorded 5 funding events for Beacon Biosignals. The most recent, Series B of $103.3M, was in Apr 2026.
Who leads Beacon Biosignals?
Jacob Donoghue is a Co-Founder and CEO at Beacon Biosignals.
What is the latest news on Beacon Biosignals?
On Apr 06, 2026, Beacon Biosignals raises $11M in a Series B extension, bringing total funding to over $97M. New investors include JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy